CRISPR Therapeutics AG
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
CRSP$50.04-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $347,559 | $298,257 |
| Marketable securities | 1,628,269 | 1,605,569 |
| Accounts receivable | — | 25,000 |
| Prepaid expenses and other current assets | 9,843 | 8,306 |
| Total current assets | 1,985,671 | 1,937,132 |
| Property and equipment, net | 115,851 | 134,093 |
| Restricted cash | 7,629 | 11,519 |
| Operating lease assets | 131,724 | 143,461 |
| Other non-current assets | 24,368 | 15,829 |
| Total assets | $2,265,243 | $2,242,034 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $11,138 | $14,709 |
| Accrued expenses | 89,407 | 41,072 |
| Deferred revenue, current | 15,771 | 3,845 |
| Accrued tax liabilities | 1,113 | 451 |
| Operating lease liabilities | 18,578 | 17,288 |
| Other current liabilities | 13,113 | 10,417 |
| Total current liabilities | 149,120 | 87,782 |
| Deferred revenue, non-current | — | 12,323 |
| Operating lease liabilities, net of current portion | 188,168 | 206,405 |
| Other non-current liabilities | 6,142 | 3,444 |
| Total liabilities | 343,430 | 309,954 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ equity: | ||
| Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at December 31, 2025 and December 31, 2024, 96,009,657 and 85,912,297 shares issued at December 31, 2025 and December 31, 2024, respectively, 95,894,341 and 85,741,981 shares outstanding at December 31, 2025 and December 31, 2024, respectively | 3,087 | 2,698 |
| Treasury shares, at cost, 115,316 and 170,316 shares at December 31, 2025 and December 31, 2024, respectively | (60) | (62) |
| Additional paid-in capital | 3,861,516 | 3,293,556 |
| Accumulated deficit | (1,947,551) | (1,365,952) |
| Accumulated other comprehensive income | 4,821 | 1,840 |
| Total shareholders’ equity | 1,921,813 | 1,932,080 |
| Total liabilities and shareholders’ equity | $2,265,243 | $2,242,034 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.